Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats

American Journal of Nephrology

Volumn 29, Issue 5, 2009, Pages 465-472

  Husain, Kazim ^a   Ferder, Leon ^a   Mizobuchi, Masahide ^b   Finch, Jane ^b   Slatopolsky, Eduardo ^b  

^a PONCE SCHOOL OF MEDICINE   (Puerto Rico)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac oxidative stress; Enalapril; Paricalcitol; Uremia

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; ENALAPRIL; GLUTATHIONE; MALONALDEHYDE; MANGANESE SUPEROXIDE DISMUTASE; PARICALCITOL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HEART INJURY; HEART PROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; UREMIA;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIOXIDANTS; DRUG THERAPY, COMBINATION; ENALAPRIL; ERGOCALCIFEROLS; FEMALE; HEART DISEASES; MALONDIALDEHYDE; NADPH OXIDASE; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; SUPEROXIDE DISMUTASE; UREMIA;

EID: 56449107904     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000178251     Document Type: Article

References (46)

1. Foley RN, Parfey PS, Sarnak MJ: Epidemiology of cardiovascular disease in chronic renal failure. J Am Soc Nephrol 1998;9:S16-S23.
2. Brewster UC, Setaro JF, Perazella MA: The renin-angiotensin-aldosterone system: car-diorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci 2003;326:15-24.
3. Anderson S, Meyer TW, Rennke HG, Brenner BM: Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985;76:612-619.
4. Kamper AL, Strandgaard S, Leyssac PP: Effect of enalapril on the progression of chronic renal failure: a randomized controlled trial. Am J Hypertens 1992;5:423-430.
5. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW: Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006;354:131-140.
6. Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, Balletta M: Co-administration of losartan and benazepril exerts additive antiproteinuric effects in IgA nephropathy. Am J Kidney Dis 2001;38:18-25.
7. Nakao N, Yoshimura A, Morita H, Takada M, Rayano T, Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting enzyme inhibitor in non-diabetic renal disease: a randomized controlled trial. Lancet 2003;361:117-124.
8. Akishita M, Nagai K, Xi H, Yu W, Sudoh N, Watanabe T, Ohara-Imaizumi M, Nagamatsu S, Kozaki K, Horiuchi M, Toba K: Renin-angiotensin system modulates oxidative stress-induced endothelial cell apoptosis in rats. Hypertension 2005;45:1188-1193.
9. Zafari AM, Ushio-Fukai M, Akers M, Yin Q, Shah A, Harrison DG, Taylor WR, Griendling KK: Novel role of NADH/NADPH oxidase-derived hydrogen peroxide in angio-tensin II induced hypertrophy of rat vascular smooth muscle cells. Hypertension 1998;32: 488-495.
10. Hattori Y, Akimoto K, Gross SS, Hattori S, Kasai K: Angiotensin II-induced oxidative stress elicits hypoadiponectinaemia in rats. Diabetologia 2005;48:1066-1074.
11. Zhang L, Ma Y, Zhang J, Cheng J, Du J: A new cellular signaling mechanism for angiotensin II activation of NF-κB: an I κB-indepen-dent, RSK-mediated phosphorylation of p65. Arterioscler Thromb Vasc Biol 2005; 25: 1148-1153.
12. Ungvari Z, Csiszar A, Kaminski PM, Wolin MS, Roller A: Chronic high pressure-induced arterial oxidative stress: involvement of protein kinase C-dependent NAD(P)H oxidase and local renin-angiotensin system. Am J Pathol 2004; 165:219-226.
13. Somani SM, Husain K, SchlorffE: Responses of physical and chemical stresses on antioxi-dant system; in Baskin S, Salem H (eds): Oxidants, Antioxidants, and Free Radicals. Washington, Taylor and Francis, 1997, pp 125-141.
14. Vaziri ND, Wang XQ, Oveisi F, Rad B: Induction of oxidative stress by glutathione depletion causes severe hypertension in normal rats. Hypertension 2000;36:142-146.
15. Husain K: Vascular endothelial oxidative stress in alcohol-induced hypertension. Cell Mol Biol 2007;53:69-76.
16. Ivanovski O, Szumilak D, Nguyen-Khoa T, Ruellan N, Phan O, Lacour B, Descamps-Latscha B, Drucke TB, Massy ZA: The anti-oxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout mice. Kidney Int 2005;67: 2288-2294.
17. Tan X, Liu Y: Paricalcitol attenuates renal interstitial fibrosis in mouse model of Obstructive nephropathy. J Am Soc Nephrol 2006;12:3382-3393.
18. 3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 1998;53:1696-1705.
19. Mizobuchi M, Morrissey J, Finch JL, Martin DR, Liapis H, Akizawa T, Slatopolsky E: Combination therapy with an angiotensin-concerting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 2007; 18:1796-1806.
20. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD: Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006;70:771-780.
21. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456.
22. Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunave Z, Light RP, Agarwal R: Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double blind pilot trial. Hypertension 2008;52:249-255.
23. Wang TJ, Pencina MJ, Booth SL, Jaques PF, Ingelsson E, Lanier K, Benjamin EJ, D'Agostino RB, Wolf M, Vasan RS: Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008;117:503-511.
24. Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B, Kinkeldei J, Boehm BO, Weihrauch G, Maerz W: Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med 2008; 168:1340-1349.
25. Inaguma D, Nagaya H, Hara K, Tatematsu M, Shinjo H, Suzuki S, Mishima T, Kurata K: Relationship between serum 1,25-dihydroxyvitamin D and mortality in patients with pre-dialysis chronic kidney disease. Clin Exp Nephrol 2008; 12:126-131.
26. Mathew S, Lund RJ, Chaudhary LR, Geurs T, Hruska KA: Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 2008;19:1509-1519.
27. Repo JM, Rantala IS, Honkanen TT, Mustonen JT, Koobi P, Tahvanainen AM, Niemela OJ, Tikkanen I, Rysa JM, Ruskoaho HJ, Porsti IH: Paricalcitol aggravates perivascular fibrosis in rats with renal insufficiency and low calcitriol. Kidney Int 2007;72:977-984.
28. Tentori F, Hunt WC, Stidly CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG: Mortality risk among hemodialysis patients receiving different vitamin analogs. Kidney Int 2006;70:1858-1865.
29. Ohkawa H, Ohishi N, Yagi K: Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-358.
30. Misra HP, Fridovich I: The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Bill Chem 1972;247:3170-3175.
31. Aebi H: Catalase in vitro. Meth Enzymol 1984;105:125-126.
32. Flohe L, Gunzler W: Assays of glutathione peroxidase. Meth Enzymol 1984; 105:114-121.
33. Read SM, Northcole DH: Minimization of variavtion in the response to different protein of the Coomassie blue G dye-binding assay for protein. Anal Biochem 1981;116:53-64.
34. Ferder LF, Inserra F, Daccordi H, Smith RD: Enalapril improved renal function and pro-teinuria in chronic glomerulopathies. Nephron 1990;55:90-95.
35. RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
36. Atkinson AB, Robertson JIS: Captopril in the treatment of clinical hypertension and cardiac failure. Lancet 1979;11:836-839.
37. Giacchetti G, Sechi LA, Rilli S, Carey RM: The renin-angiotensin- aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab 2005;16:120-126.
38. Zanetti M, Barazzoni R, Guamierie G: Inflammation and insulin resistance in uremia. J Ren Nutr 2008; 18:70-75.
39. 3 is a negative endocrine regulator of renin angiotensin system. J Clin Invest 2002; 110:229-238.
40. 3 as novel inhibitors of renin biosynthesis. J Steriod Biochem Mol Biol 2005;96:59-66.
41. Guijarro C, Egido J: Transcription factor kappa-B (NF-kB) and renal disease. Kidney Int 2001;58:415-424.
42. 3 targetingof NF-κB suppresses high glucose-induced MCP-1 expression in me-sangial cells. Kidney Int 2007;72:193-201.
43. Younes M, Siegers CP: Mechanistic aspects of enhanced lipid peroxidation following glutathione depletion in vivo. Chem Biol Interact 1981;34:257-266.
44. Bondy SC: Ethanol toxicity and oxidative stress. Toxicol Lett 1992;63:231-241.
45. Guo Z, Boekhoudt GH, Boss JM: Role of the intronic enhancer in tumor necrosis factor-mediated induction of manganese superoxide dismutase. J Biol Chem 2003;278:23570-23578.
46. Salo DC, Pacifici RE, Lin SW, Giulivi C, Davies KJ: Superoxide dismutase undergo pro-teolysis and fragmentation following oxidative modification and inactivation. J Biol Chem 1990;265:11919-11927.